| HOME >> MEDICINE >> TECHNOLOGY |
Company Strategy 100
Company Strategy (Continued) 101
CHAPTER FIVE: BIOMARKERS 102
INTRODUCTION 102
TABLE 45 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($
MILLIONS) 103
ENABLING ADVANCEMENTS DRIVING MARKET GROWTH 103
BIOMARKERS DRIVE SPEED, COST AND QUALITY
IMPROVEMENTS ACROSS THE DRUG DEVELOPMENT
SPECTRUM 103
BIOMARKERS APPLICATIONS: DRUG DEVELOPMENT 104
Safety/Toxicology Biomarkers 105
Dose Selection and Dose Optimization 105
Improved Measurement of Therapeutic Efficacy 105
Outcome Biomarkers and Surrogate Endpoints 105
EARLY-STAGE CLINICAL TRIAL APPLICATIONS 106
LATE-STAGE CLINICAL TRIAL APPLICATIONS 107
Phase III 107
Phase IV 107
BIOMARKERS: CHALLENGES AND OPPORTUNITIES 107
SUMMARY 107
CLINICAL VALIDITY: REQUIREMENTS 108
BIOMARKER OPPORTUNITIES 108
PRODUCT SUMMARY AND MARKET 108
GENOMICS 108
TABLE 46 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($
MILLIONS) 109
IMAGING 109
PROTEOMICS 110
BIOINFORMATICS 110
OTHER 111
Metabonomics 111
BIOMARKER ADOPTION BY THE PHARMACEUTICAL
INDUSTRY 111
GROWTH DRIVERS AND RESISTORS 111
FACTORS INFLUENCING BIOMARKER ADOPTION IN
CLINICAL TRIALS 111
CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE 112
IMPACT OF DRUG FAILURE IN LAST-STAGE CLINICAL
TRIALS 112
Merck: Vicriviroc 112
ADDITIONAL CAPABILITIES BY LARGE SERVICE
PLAYERS 113
TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND
PROTEOMICS 113
BIOMARKER MARKET FORECAST 114
TABLE 47 GLOBAL BIOMARKER MARKET FORECAST, THROUGH
2015 ($ MILLIONS) 114
REGULATORY ENVIRONMENT 114
INTRODUCTION 114
ROLE OF THE FOOD AND DRUG ADMINISTRATION 114
TABLE 48 FDA GUIDELINES FOR BIOMARKER APPLICATIONS 115
EUROPEAN MEDICINES AGENCY 116
'/>"/>| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |